Tekla Capital Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Tekla Capital Management’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$40.3K	Hold	5,143	–	–	﹤0.01%	163
2023 Q1	$37.4K	Sell	5,143 -1	-0%	-$4	﹤0.01%	174
2022 Q4	$17.1K	Hold	5,144	–	–	﹤0.01%	169
2022 Q3	$25K	Hold	5,144	–	–	﹤0.01%	165
2022 Q2	$39K	Hold	5,144	–	–	﹤0.01%	174
2022 Q1	$82K	Hold	5,144	–	–	﹤0.01%	171
2021 Q4	$95K	Sell	5,144 -8,639	-63%	-$234K	﹤0.01%	167
2021 Q3	$422K	Hold	13,783	–	–	0.01%	164
2021 Q2	$757K	Hold	13,783	–	–	0.02%	176
2021 Q1	$815K	Hold	13,783	–	–	0.03%	181
2020 Q4	$517K	Hold	13,783	–	–	0.02%	190
2020 Q3	$744K	Buy	13,783 +1,159	+9%	+$210K	0.03%	187
2020 Q2	$3.18M	Buy	+12,624	New	+$2.55M	0.12%	136

Other funds holding CRBP

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Tekla Capital Management's CRBP Position: Q2 2023 in Review

Tekla Capital Management held its Corbus Pharmaceuticals (CRBP) position steady in Q2 2023 at 5,143 shares worth $40.3K. The position accounts for ﹤0.01% of the portfolio, ranked #163.

Tekla Capital Management first reported a position in CRBP in Q2 2020 and has held it in 13 quarters since. The position peaked at $3.18M in Q2 2020. 28 funds tracked by Wall St. Rank hold CRBP as of Q2 2023.

Tekla Capital Management held 5,143 shares of Corbus Pharmaceuticals worth $40.3K as of Q2 2023.
Tekla Capital Management left its Corbus Pharmaceuticals share count unchanged in Q2 2023.
Corbus Pharmaceuticals made up ﹤0.01% of Tekla Capital Management's portfolio in Q2 2023, its #163 holding.
Tekla Capital Management first reported a position in Corbus Pharmaceuticals in Q2 2020 and has held it in 13 quarters since.
Tekla Capital Management's Corbus Pharmaceuticals position peaked at $3.18M in Q2 2020.
28 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.